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Adoptive therapy with mesenchymal stem cells (MSC) is
being developed as a promising approach in the treatment
of graft-vs-host disease (GVHD). In vitro, MSC exhibit
strong immunomodulatory properties toward alloantigen-
induced T-cell responses [1], and although evidence from
in vivo mouse models is conflicting [2] in clinical practice,
systemically delivered MSC have been proven effective in
reducing GVHD [3]. Multipotent adult progenitor cells
(MAPC), a recently described population of nonhemato-
poietic bone-marrowderived stem cells with a broader
differentiation capacity than MSC, have currently received
attention as an alternative source for immunomodulatory
cell therapy. Human MAPC can be expanded forO60 popu-
lation doublings, which should allow use of a single-donor
cell bank to treat large patient numbers. Kovacsovics-
Bankowski et al. have reported that clinical-scaleexpanded
rat MAPC, following systemic delivery, can inhibit rat
GVHD lethality [4], and the first clinical trial with large-
scaleexpanded human MAPC (MultiStem) for GVHD
has been initiated. More recently, Highfill et al. reported that
mouse MAPC (mMAPC) suppress in vivo T-cell allores-
ponses and GVHD provided they are delivered intraspleni-
cally at the site of initial T-cell alloactivation [5].
We have studied the immunomodulatory behavior of
mMAPC-2, an mMAPC clone we described previously, to
express significant amounts of the embryonic transcription
factor Oct4 (510% of murine embryonic stem cells
[mESC]), as well as primitive endoderm transcripts
(Gata4;Gata6;Sox7;Sox17) [6,7], and to differentiate to
cells with endothelium, hepatocyte, and neural progenitor
characteristics [6,7]. This MAPC clone is similar to the
clone reported on by Highfill et al. [5]; however, although
our in vivo data underscore the potential of mMAPC for
GVHD-immunomodulation, the in vitro data indicate that
mMAPC also can exert immunostimulatory actions in an
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To investigate the in vivo immunomodulatory effects of
mMAPC-2 (C57BL/6 origin), we used the C57BL/6(H-2b)/
CB17/SCID(H-2d) major histocompatibility complex
(MHC)disparate model of local GVHD (popliteal lymph
node assay) and systemic GVHD. In popliteal lymph node
assay, we injected 10  106 purified C57BL/6 T-cells (pan-
T-cell kit, MACS; Miltenyi Biotec Gmbh, Germany) with 5
 106mMAPC-2 in the footpad of natural killer celldepleted
(anti-asialoGM1, Wako, Germany) CB17/SCID mice; in the
contralateral footpad only C57BL/6 T cells were injected.
After 1 week, TCR-Vb3þ-expressing alloreactive T-cell
frequency was determined in popliteal lymph nodes using
flow cytometry (anti-mouse TCR-Vb3-phycoerythrin and
CD3-peridinin chlorophyll monoclonal antibody; Becton
Dickinson Biosciences, Erembodegem, Belgium). For
induction of systemic GVHD, natural killer celldepleted
CB17/SCID mice received intravenous injections of 0.5 
106 purified C57BL/6 T-cells on day 0, with or without co-
injected 0.5  106 mMAPC-2 on days 0 to 21 (5 injections),
0 to 14 (5 injections), or 1 to 13 (4 injections) (3 indepen-
dent experiments); GVHD outcome was monitored based
on body weight and clinical GVHD score. In vitro, the
immunomodulatory effect of mMAPC-2 on C57BL/6(H-
2b)/BALB/c(H-2d) mixed lymphocyte reaction (MLR)
was compared to that of mMSC (D Prockop, Tulane Univer-
sity, New Orleans, LA, USA) and mESC (both C57BL/6
origin). Mitomycin-Ctreated mMAPC-2, mESC, mMSC
were added on day 0 at four different suppressor-to-effector
(S:E) ratios (1:100 to 1:1) to the MLR (MACS-purified
(C57BL/6) CD4þ T-cells 4 (MACS-purified þ mito-
mycin-Ctreated) (BALB/c) splenic CD11cþ dendritic
cells). After a 4-day culture, T-cell-proliferation was
measured (3H-thymidine incorporation or carboxy fluores-
cein succinimidyl ester dilution in the viable cell population
(7-amino-actinomycin D and Annexin-V).
Results and discussion
In vivo, mMAPC-2 efficiently suppressed alloreactive T-cell
expansion in popliteal lymph node assay: mean TCR-Vb3þ-
expressing alloreactive T-cell frequencies were 19.14% 6
2.8% standard error (SE) and 6.79%6 2.6% SE in the T cell,
respectively. T-cellþmMAPC-2injected limbs ( p5 0.001,
Wilcoxon rank-sum test; n 5 8/group, n 5 6 independent
experiments). However, in the systemic GVHD model, both
the T-cell þ mMAPC-2treated and the T-cellonly groupology and Stem Cells. Published by Elsevier Inc.
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intravenously delivered mMAPC-2 to suppress systemic
GVHD in our model and that of Highfill et al. [5] is consistent
with previous mouse studies on the failure of MSC to inhibit
systemic GVHD [2]; however, our data confirm the potential
of mMAPC to modulate in vivo graft-vs-host reactivity,
provided they are delivered locally at the site of initial T-cell
alloactivation. In contrast to the invitro data obtained byHigh-
fill et al. [5], however, we documented thatmMAPC-2 consis-
tently exert a bimodal modulatory effect on in vitro
alloreactive T-cell proliferation, with an immunostimulatory
effect at low S:E ratios (e.g., 5% and 66% stimulation at S:E
1:100, 1:10, respectively) and a suppressive effect at high
S:E ratios (e.g., 81% suppression at S:E 1:1) (one of five inde-
pendent assays). In contrast, simultaneously tested mMSC
and mESC exerted a dose-dependent suppressive effect,
consistent with literature (e.g,. 38%, 38%, 81% for mMSC
and 0%, 32%, 83% for mESC at S:E 1:100, 1:10, and 1:1)
[1,8]. An identical bimodal immunomodulatory pattern was
documented with mMAPC-1, a clone with transcriptome and
functional properties identical to mMAPC-2 [6]. When
mMAPC-2 were separated from the MLR by a 0.4-mm pore
size membrane (Transwell; Corning Incorporated, Corning,
NY, USA), the immunostimulatory effect disappeared while
immunosuppressive effects were preserved, indicating that
mMAPC-mediated immunostimulation is contact-dependent
and suppression is contact-independent. In contrast to what
is known for mouse and human MSC [1], and in contrast to
Highfill et al. [5], inhibiting PGE2 and inducible nitric oxide
synthase synthesis did not inhibitmMAPC-2 immunosuppres-
sion. The mechanisms involved in the immunostimulatory
effects are as yet undetermined.
In summary, we conclude that Oct4high mMAPC-2
suppress in vivo graft-vs-host reactivity provided they are
delivered locally at the site of initial T-cell alloactivation,
confirming the potential of mMAPC for GVHD immuno-
suppression as recently reported by Highfill et al. [5] These
findings emphasize the critical role of stem-cell homing to
sites of T-cell alloreactivity and this has important implica-
tions for future clinical applications. However, as evident
from the contrast between our findings and those of Highfill
et al. [5], similar MAPC-populations exhibit functional
differences in vitro, and our data particularly suggest that
immunostimulatory effects may hold safety concerns for
in vivo application. There is also evidence that murineMSC
are not intrinsically immunoprivileged: a bimodal in vitro
immunomodulatory effect has also been reported for human
and mouse MSC [9] and, moreover, there is evidence in
mice that MSC, under specific conditions, can induce
a memory T-cell response in allogeneic hosts [10]. In view
of the difficulty to correlate in vitro and in vivo immuno-
modulatory effects of e.g., MSC, our data warrant that func-
tional differences between similar stem cell types should be
considered when contemplating the use of a given cell-line
for immunomodulation in specific disease-contexts.Acknowledgments
A.L. is a doctoral fellow of the Institute for the Promotion of Inno-
vation by Science and Technology in Flanders. L.D.S. is a doctoral
fellow and A.D.B a postdoctoral fellow of the Flanders National
Fund for Scientific Research. We thankfully acknowledge Martine
Geraerts for help onMAPC cultures and Caroline Lenaerts for tech-
nical support.Conflict of Interest Disclosure
No financial interest/relationships with financial interest relating
to the topic of this article have been declared.
Ariane Luyckxa,*
Lien De Somera,*
Omer Rutgeertsa
Mark Waera
Catherine M. Verfaillieb
Stefaan Van Goolc
An D. Billiaua
aLaboratory of Experimental Transplantation
bStem Cell Institute
cLaboratory of Experimental Immunology, University of
Leuven, Leuven, Belgium
*Drs. Luyckx andDeSomer contributed equally to thiswork.
References
1. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal
stromal cells. Blood. 2007;110:3499–3506.
2. Sudres M, Norol F, Trenado A, et al. Bone marrow mesenchymal stem
cells suppress lymphocyte proliferation in vitro but fail to prevent
graft-versus-host disease in mice. J Immunol. 2006;176:7761–7767.
3. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for
treatment of steroid-resistant, severe, acute graft-versus-host disease:
a phase II study. Lancet. 2008;371:1579–1586.
4. Kovacsovics-Bankowski M, Streeter PR, Mauch KA, et al. Clinical
scale expanded adult pluripotent stem cells prevent graft-versus-host
disease. Cell Immunol. 2009;255:55–60.
5. Highfill SL, Kelly RM, O’Shaughnessy MJ, et al. Multipotent adult
progenitor cells (MAPC) can suppress graft-versus-host disease via
prostaglandin E2 synthesis and only if localized to sites of alloprim-
ing. Blood. 2009;114:693–701.
6. Ulloa-Montoya F, Kidder BL, Pauwelyn KA, et al. Comparative tran-
scriptome analysis of embryonic and adult stem cells with extended
and limited differentiation capacity. Genome Biol. 2007;8:R163.
7. Serafini M, Dylla SJ, Oki M, et al. Hematopoietic reconstitution by
multipotent adult progenitor cells: precursors to long-term hematopoi-
etic stem cells. J Exp Med. 2007;204:129–139.
8. Koch CA, Geraldes P, Platt JL. Immunosuppression by embryonic
stem cells. Stem Cells. 2008;26:89–98.
9. Le Blanc K, Rasmusson I, Go¨therstro¨m C, et al. Mesenchymal stem
cells inhibit and stimulate mixed lymphocyte cultures and mitogenic
responses independently of the major histocompatibility complex.
Scand J Immunol. 2003;57:11–20.
10. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived
mesenchymal stem cells are immunogenic in an allogeneic host and
stimulate donor graft rejection in a nonmyeloablative setting. Blood.
2006;108:2114–2120.
